Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 80% Generic Share “at Early Date,” Essential Drug Supplies Join Draft Fiscal Policy Blueprint
June 23, 2015
- PMDA, AMED Plan to Enter Partnership Agreement; Share Information to Promote Commercialization of Seeds
June 23, 2015
- Editor’s Pick: Five Healthcare News Headlines for June 8 - June 21
June 22, 2015
- AMED’s Screening Consortium “Won’t Harm Companies”: Official
June 22, 2015
- AMED to Build Library of Middle-Molecule Compound
June 22, 2015
- No Progress for Wholesalers’ Negative Primary Margin on Sales, Single-Product, Single-Price Deals Stagnant: Ryukaikon
June 19, 2015
- Set Earlier-than-FY2020 Date for 80% Generic Target: Govt Working Group
June 19, 2015
- MOF Generic Target, Reference Pricing Rollout “Impossible”: LDP Panel
June 19, 2015
- First Generics for Plavix to Join NHI Price List on June 19
June 18, 2015
- Ryukaikon to Push Single-Product, Single-Price Deals in New Proposal Due Out Summer
June 18, 2015
- Measures Would Be Necessary if Generic Brands Continue to Increase Due to Joint Development: MHLW Official Jo
June 18, 2015
- PAFSC 2nd Committee Supports Approval of Olanexidine, New Indication for Zosyn
June 18, 2015
- Govt Deregulation Panel Calls for Revisiting 14-Day Prescription Limit
June 17, 2015
- MHLW Designates Ceritinib as Orphan Drug
June 17, 2015
- Govt Working Group Calls for Switching Contract Manufacturing of Long-Listed Drugs to Generic Production
June 16, 2015
- Takeda Slapped with Business Improvement Order over CASE-J
June 12, 2015
- Accession Requirements for ICH Assembly Hammered Out at Fukuoka Confab
June 12, 2015
- LDP Compiles Proposal for Govt Growth Strategy, Including Target for Sakigake System
June 12, 2015
- Abe of JPA Proposes Exempting Ordinary Pharmacies from Medical Fee Cut Rule: Chuikyo
June 12, 2015
- Shiozaki’s Pitch on 80% Generic Target by FY2020 Fails to Resonate
June 11, 2015
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…